Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

This study has been terminated.
(The primary efficacy endpoint was not met)
Information provided by (Responsible Party):
Lux Biosciences, Inc. Identifier:
First received: March 12, 2007
Last updated: October 9, 2012
Last verified: October 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2010
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):